Pharmaceuticals

Stock Code

MYX

Stock Exchange

ax

Mayne Pharma (MYX) was known as FH Faulding & Co where amongst other activities including pharmaceutical wholesaling and consumer health products, it built success around optimising the delivery of oral dosage form drugs. In 2001, Mayne Group Ltd acquired FH Faulding & Co and then in November 2005, Mayne Group Ltd demerged the business. MYX was listed on the Australian stockmarket (ASX) on 29 June, 2007.

Mayne Pharma Limited

A global pharmaceutical company focused on research and development, manufacture, marketing and distribution of injectable and oral pharmaceuticals; and

Stock Code

BNC

Stock Exchange

ax

Bioniche Life Sciences Inc (BNC) is a biopharmaceutical company. The Company develops, manufactures and markets products for human and animal health markets worldwide. It operates in three segments: human health, animal health and food safety. BNC was listed on the Australian stockmarket (ASX) on 27 January, 2011.

Human Health

Stock Code

HXL

Stock Exchange

ax

Hexima (HXL) is a company that focues on agricultural biotechnology. The company engages in the research and development of technology for the genetic modification of crops, primarily to enhance their resistance to insects and fungal pathogens. It was listed on the Australian stock market on 27 August, 2007. Investors can trade Hexima shares on the Australian Stock Exchange (ASX).

Telesso Technologies (TEO), formerly EIF is involved in chemically re-engineering drugs to improve performance (potentially reducing dosage and side effects) and allowing use of more efficient, patient-friendly, drug delivery options (i.e. oral, inhalable, injectable, transdermal and implants). The company is also involved in the re-engineering of existing drugs to improve their patent life. Investors can trade Telesso Technologies shares on the Australian Stock Exchange (ASX).

Stock Code

TDX

Stock Exchange

ax

Tyrian Diagnostics (TDX) is an Australian-based company which develops and commercialises rapid point-of-need diagnostics for clinical and non-clinical applications. Tyrian’s objective is to generate recurring revenues from a portfolio of rapid point-of-need diagnostic products. The Company’s strategy is to deliver near term revenues through commercialisation of clinical and agricultural products on its patented DiagnostIQTM platform. Longer term, Tyrian intends to develop higher value proprietary products for respiratory infectious disease.

Pallane Medical is the new name for Dia-B. Dia-B Tech Limited’s underlying strategy and objective is the discovery and development of pharmaceuticals, diagnostics and treatments for diabetes and diabetes-related diseases. The company's primary focus is to further develop its most advanced project, ISF402, to take to human trials in mid-2006 with the aim of providing a safe glucose lowering drug, likely to be taken orally. Dia-B is structured to run as a “virtual operation” with low overhead costs.

Immuron (IMC) is a biotechnology R&D company focussed on the development, manufacture and commercialisation of nutraceutical, pharmaceutical and related therapeutic technology products, primarily for use in and by, humans. IMC developes natural pharmaceuticals from dairy fractions and colostrum. Investors can trade Immuron shares on the Australian Stock Exchange (ASX).

Stock Code

HCT

Stock Exchange

ax

Holista CollTech (HCT), earlier called CollTech Australia (CAU) has been formed through the merger of CollTech Australia with Holista Biotech Sdb Bhd. The company focuses on natural ingredients for health supplements and lifestyle products. HCT aims to commercialise the extraction and purification of collagen from a unique source sheep (ovine) skins. HCT has patent protection filed over all intellectual property. Investors can trade shares on the Australian Stock Exchange (ASX).

Stock Code

GBI

Stock Exchange

ax

Genera Biosystems (GBI) is an Australian publicly listed company that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera's products compete in the global market for molecular diagnostic tests - currently valued at around US$2.6 billion, and expected to double in the next five years - and are used by commercial pathology providers. Investors can trade Genera Biosystems shares on the Australian Stock Exchange (ASX).

Stock Code

FLS

Stock Exchange

ax

Fluorotechnics (FLS) develops and sells innovative consumables and small equipment that enable scientists to better measure biological processes using fluorescence. The company has established itself as an emerging leader in the supply of products which are environmentally friendly, safe to use and offer a unique solution and superior performance compared to existing products. These products are used globally by their customers in research, quality control and diagnostics. Investors can trade Fluorotechnics shares on the Australian Stock Exchange (ASX).